Research Projects & Grants

Federal

  • Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), Role: Investigator, National Institute of Allergy and Infectious Diseases/NIH/DHHS, Status: Completed

For Profit Organization

  • Evaluation of the safety and pharmacodynamic effect of AGN-151607 by measuring the compound muscle action potential (CMAP) of the extensor digitorum brevis ( EDB) muscle following a single injection in healthy subjects. Protocol 1925-101-008, dated 18 August 2017. Informed consent form version dated 30 August 2017, Role: Investigator, Allergan Inc., (08/2018 - 08/2019) Status: Completed
  • A multicentre, randomized, placebo-controlled,double-blind study of the efficacy, safety, and pharmacokinetics of lubiprostone in paediatric subjects ages >/= 6 years to < 18 years with functional constipation., Role: Investigator, Sucampo Pharmaceuticals, Inc., (04/2016 - 04/2017) Status: Completed
  • A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, homozygous for the F508del-CFTR mutation, Role: Investigator, Vertex Pharmaceuticals Incorporated (Vertex), (05/2014 - 05/2015) Status: Completed
  • A multi-center, double-blind, randomized, active-controlled study to evaluate two formulations of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (9525X and 9060X) by measuring the compound muscle action potential (CMAP) of the Extensor Digitorum Brevis (EDB) muscle in response to a single intramuscular injection of varying doses in the EDB muscle of healthy volunteers (Protocol Number: 191622-051), Role: Investigator, Allergan Inc., (02/2005 - 02/2006) Status: Completed
  • The clomethizole acute stroke study in acute ischemic stroke (class-I): a double blind, parallel group, multinational, multicenter study of the efficacy and safety of i.v. clomethiazole compared to placebo in patients with acute ischemic stroke. Study code: SA-CMZ-0009 (Protocol dated 08/21/97 and Amendment No. 1 dated 06/23/98)., Role: Investigator, ASTRA (USA), (07/2000 - 07/2001) Status: Completed
  • LY333328 vs Vancomycin in skin/skin-structure infections, Role: Investigator, Eli Lilly & Co., (12/1999 - 12/2000) Status: Completed

Internal

  • Evaluation of providers’ concordance with 2017 IDSA/SHEA Clostridioides difficile treatment guideline updates to develop targeted education for the adaptation of the 2021 IDSA/SHEA guideline update at Loma Linda University Medical Center, Role: Investigator, LLU Dept. of Pharmacy Practice, (10/2021) Status: Approved
  • Characterizing Opportunities for Pharmacist-Initiated Interventions on an Outpatient Parenteral Antimicrobial Therapy (OPAT) Service, Role: Investigator, LLU Dept. of Pharmacy Practice, (07/2021) Status: Approved
  • Evaluation of safety in pediatric patients on titratable heparin drips utilizing activated partial prothrombin time (aPTT) versus both aPTT and anti-factor Xa monitoring, Role: PI, LLU Dept. of Pharmacy Practice, (03/2021) Status: Approved

Non-Profit Organization

  • An open-label study in subjects with Parkinson's disease to evaluate the safety and tolerability of titration and continuous subcutaneous infusion of ABBV-951 for up to 4 weeks in an outpatient environment. Protocol: M15-739, Role: Investigator, AbbVie, Inc., (11/2019 - 11/2020) Status: Completed